Research Pharmacy (Investigational Drug Service, IDS)

A research pharmacy — also called an Investigational Drug Service (IDS), investigational pharmacy, or clinical trials pharmacy — is the pharmacy function that manages investigational product (IP) across its lifecycle within a clinical trial: receipt from the sponsor or its distributor, storage under specified conditions, inventory accountability, randomization/blinding support, preparation and dispensing against protocol-specific orders, and eventual return, reconciliation, or destruction of unused product. It is organizationally and functionally distinct from a routine hospital or retail pharmacy, which dispenses commercially available, FDA- or equivalent regulator-approved medications against standard prescriptions with no sponsor accountability obligations.

The function exists because investigational product carries regulatory and scientific requirements that ordinary pharmacy workflows are not built to satisfy: chain-of-custody documentation sufficient to support a regulatory inspection, blinding integrity that must be preserved from everyone except designated unblinded staff, and dispensing tied to trial eligibility and randomization rather than an open-ended prescription. See CASRAI’s Investigational Medicinal Product (IMP) entry for the regulatory definition of the product itself.

Core responsibilities

• Receipt and storage — verifying shipments against sponsor shipping manifests, storing product under the temperature and security conditions specified in the protocol/pharmacy manual (often requiring dedicated refrigeration, freezer, or controlled-room-temperature storage with continuous monitoring), and segregating investigational stock from commercial inventory.
• Drug accountability — maintaining a complete, auditable record of every unit of investigational product from receipt through final disposition (dispensed, returned to subject, returned to sponsor, or destroyed on-site), reconciled against dispensing logs and subject visit records. This accountability log is one of the documents a sponsor’s clinical research associate (CRA) reviews at monitoring visits and one that regulatory inspectors examine directly.
• Randomization and blinding support — in blinded trials, an unblinded pharmacist (or a designated unblinded team member) accesses the randomization code to prepare, label, or dispense product and matching comparator/placebo so that treatment assignment remains concealed from the treating investigator, study coordinator, and subject. The unblinded pharmacist typically has no role in subject assessment, to preserve the independence the blind depends on.
• Protocol-specific dispensing — verifying subject eligibility, confirming an active, IRB/ethics-committee-approved protocol and current informed consent, and dispensing only the dose and formulation specified for that subject’s visit and randomization arm, rather than against an open prescription.
• Compounding and preparation — when the investigational product requires reconstitution, dilution, or other preparation (common in oncology and infusion trials), performing this under the same GCP and, where applicable, USP compounding standards that apply to any sterile or non-sterile preparation.
• Return, reconciliation, and destruction — documenting unused, expired, or discontinued product returned by subjects, and either returning it to the sponsor or destroying it on-site under a sponsor-authorized destruction procedure, with the destruction itself documented and, in many programs, witnessed.

Regulatory basis

ICH E6(R2) Good Clinical Practice Section 5.14, “Supplying and Handling Investigational Product(s),” places the underlying obligation on the sponsor to ensure timely delivery of investigational product and to maintain systems and written procedures for shipment, receipt, storage, dispensing, retrieval of unused product, and return or destruction — obligations a research pharmacy typically executes on the sponsor’s and investigator’s behalf at the site level. Section 4.6 (Investigational Product(s)) similarly assigns the investigator/institution responsibility for accountability, and explicitly contemplates that this responsibility “may be delegated to a pharmacist or another appropriate individual who is under the supervision of the investigator/institution.” A research pharmacy is, functionally, the site’s mechanism for discharging that delegated accountability obligation. ICH E6(R3), now in effect in the EU and covered by final FDA guidance, carries the same underlying principle forward. Records the pharmacy maintains — shipment, receipt, disposition, and destruction logs — form part of the site’s essential documents and, by extension, the trial’s Trial Master File (TMF).

In the US, ASHP (American Society of Health-System Pharmacists) maintains a dedicated Investigational Drug Services resource area and published guidelines — including its Guidelines for the Management of Investigational Drug Products — describing the operational standards (staffing, training, inventory control, documentation) research pharmacies are expected to meet; HOPA (the Hematology/Oncology Pharmacy Association) publishes complementary IDS best-practice standards aimed at oncology trials specifically, where preparation and accountability requirements are typically more demanding. Institutions distinguish research pharmacy staff and space requirements from routine pharmacy operations in staffing plans, and many academic medical centers and hospital systems operate an IDS as an identifiable unit within or alongside the main pharmacy department, sized and resourced according to trial volume.

Research pharmacy vs. hospital pharmacy

The distinction is functional, not merely organizational. A hospital pharmacy dispenses approved medications against a prescriber’s order, governed by hospital formulary and pharmacy-practice regulation, with no sponsor-facing accountability obligation and no blinding function. A research pharmacy operates under an additional, protocol-specific layer: sponsor shipping/storage instructions, trial-specific accountability logs subject to monitor review and regulatory inspection, and, for blinded trials, a randomization-code access control that has no equivalent in standard dispensing. The same institution’s pharmacy department often performs both functions, but the research/IDS function is typically staffed, trained, and audited separately because the compliance obligations differ.

Where it fits in trial operations

Research pharmacy activity is one part of the broader investigational-product supply chain a trial’s sponsor and site must manage across the study; see CASRAI’s Clinical Trial Supply Management guide for how IP forecasting, distribution, and site-level accountability fit together, and the Decentralized Clinical Trials guide for how direct-to-participant and specialty-pharmacy shipment models change (without eliminating) the accountability and chain-of-custody obligations a research pharmacy normally handles on-site. Research pharmacy staffing and per-dispense costs are also a real line item in overall trial budgeting; see the Cost of Running a Clinical Trial guide.

Related terms

• Investigational Medicinal Product (IMP) — the regulatory definition of the product the research pharmacy handles.
• Trial Master File (TMF) — the essential-documents structure into which the pharmacy’s accountability and destruction logs feed.
• ICH E6(R2) — the GCP guideline establishing the underlying investigational-product handling and accountability obligations.